[建立一种分级方法,以避免HLA类I抗体对应抗原和结合HLA匹配器应用在IPTR患者血小板输血后改善CCI值]
Su-Qing Gao1, Yun-Ping Xu2, Chang-Ru Luo3
1Shenzhen Blood Center Institute of Transfusion Medicine;Shenzhen 518040, Guangdong Province, China.E-mail:gaosuqing1@163.com.
Zhongguo shi yan xue ye xue za zhi
|February 22, 2024
概括
选择HLA I类兼容血小板的新分级方法有效地改善了免疫血小板输血失败 (IPTR) 患者的校正计数增量 (CCI),通过避免基于抗体水平的特定供体抗原.
科学领域:
- 免疫学 免疫学 免疫学
- 输血医学 输血医学
- 遗传学 遗传学 是一个
背景情况:
- 免疫血小板输血失败 (IPTR) 在需要血小板输血的患者的管理中提出了重大挑战.
- 目前选择HLA兼容血小板的方法通常依赖于平均光强度 (MFI) 值,这些值可能不够细致.
- 该HLAMatchmaker程序通过最小化表位组不匹配来帮助选择捐赠者,但其与抗体特异性的整合需要评估.
研究的目的:
- 开发和评估一种分级的方法,以避免HLA类I抗体对应的抗原.
- 评估这种分级回避方法和HLAMatchmaker程序在IPTR患者中选择HLA兼容血小板的联合应用.
- 确定这种综合策略对改善血小板输血疗效的影响,通过校正计数增量 (CCI) 测量.
主要方法:
- 在51名IPTR患者的7,807个血小板交叉匹配测试中利用固相红细胞粘附率 (SPRCA).
- 采用Luminex单抗原流细胞计检测HLA I类抗体,并对其MFI水平进行分级 (强,中,弱,负).
- 结合HLAMatchmaker表皮质不匹配分析与分级抗原回避用于供体选择,其次是输血后的CCI计算.
主要成果:
- 在强,中和弱的HLA类I抗体组中观察到SPRCA结果的统计学上显著差异 (P<0.001).
- 强和中等阳性抗体组与负对照组相比显示出显著差异,而弱组没有 (P > 0.05).
- 一种避免HLA类I抗体抗原1级 (强) 和2级 (中等) 的策略,结合HLAMatchmaker得分≤7,产生CCI值>4.5×109/L.
结论:
- 对HLA类I抗体对应抗原的分级回避策略,加上HLAMatchmaker,对于在IPTR中选择兼容的捐赠者是有价值的.
- 这种综合方法在提高血小板输血效率方面具有实际效用.
- 证实负面结果的血小板交叉匹配实验对于改善IPTR患者的血小板计数至关重要.
相关概念视频
Tissue Transplantation
366
Tissue transplantation is a significant medical procedure involving the transfer of cells, tissues, or organs from a donor to a recipient, with the primary aim of restoring lost functions. This procedure is crucial in treating a broad spectrum of diseases, including kidney diseases, liver failure, heart disease, and certain types of cancers.
The Biology of Tissue Transplantation
The biology of tissue transplantation hinges on the Major Histocompatibility Complex (MHC) molecules. These molecules...
The Biology of Tissue Transplantation
The biology of tissue transplantation hinges on the Major Histocompatibility Complex (MHC) molecules. These molecules...
366
Bone Marrow Sampling and Transplants
330
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
330
Blood Transfusion and Agglutination
10.8K
Blood transfusion is a therapeutic measure to restore the blood volume after extensive blood loss due to an accident or a medical procedure. Blood transfusion involves drawing a certain amount of blood from a suitable donor and infusing it into the recipient.
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...
10.8K


